Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Non-Small Cell Lung
Interventions: DRUG: ATI-1123 (active drug = docetaxel)
Sponsor: Azaya Therapeutics, Inc.